CJC-1295 + Ipamorelin: The Growth Hormone Stack

What this stack does.

CJC-1295 is a growth-hormone-releasing hormone (GHRH) analogue that binds to albumin in the bloodstream, creating a sustained elevation of GH release over hours. Ipamorelin is a ghrelin mimetic: it stimulates the pituitary to release GH in pulses, but does so with minimal effect on prolactin or cortisol, which are common side effects of other secretagogues.

Combined, they work in complementary windows. CJC-1295 establishes a baseline GH secretion capability; Ipamorelin adds focused pulses within that window. Research shows this pairing delivers a more robust and physiologically balanced GH response than either compound alone. The result is higher circulating GH without the hormonal noise that makes some men feel wired, bloated, or suppressed.

Users in the recovery space report faster soft-tissue healing, improved sleep architecture, and lean-mass gains when stacked correctly. The mechanism is permissive, not forceful: you are restoring a signalling pathway rather than flooding the system.

Who it's for.

This stack is built for the man returning to serious training after injury, surgery, or extended layoff. You are 35 or older. You have trained hard enough to know what full recovery feels like, and you are frustrated by the slow creep back to baseline. You understand that GH recovery is real, measurable, and worth the protocol investment.

You are skeptical of claims but willing to run a structured experiment if the mechanism is sound and the research is there. You read papers. You know the difference between preclinical data and human outcome studies, and you accept the gap. You are not looking for a magic pill; you are looking for a tool that addresses the legitimate metabolic tax of hard training and biological age.

This is not for men chasing rapid fat loss or aggressive lean-mass gain in a vacuum. This is for recovery, tissue quality, and resilience.

The protocol.

CJC-1295 (non-DAC formulation recommended): 100 micrograms per dose, once daily, dosed in the evening (18:00 to 21:00). Subcutaneous injection. Cycle: 12 weeks on, 2 weeks off. The non-DAC version clears faster and allows for easier troubleshooting if side effects emerge.

Ipamorelin: 100 micrograms per dose, three times daily: morning (fasted, pre-training if training occurs then), mid-afternoon (fasted or light food), and evening (30 minutes before CJC-1295 injection, fasted). Subcutaneous injection. Cycle: 12 weeks on, 2 weeks off, synchronised with CJC-1295.

Timing and food state: Ipamorelin works best on an empty stomach or very light carbs (black coffee, zero-calorie drinks acceptable). Inject 30 minutes before any meal if possible. The evening Ipamorelin should precede CJC-1295 by 30 minutes to allow the GH pulse to prime the GHRH signalling window. If training in the morning, inject Ipamorelin 15 minutes pre-training; GH response will support intra- and post-training recovery signalling.

Reconstitution: Both compounds arrive as lyophilized powder. Use bacteriostatic water (0.9% sodium chloride with 0.9% benzyl alcohol). Refer to /tools/reconstitution-calculator for exact volumes. Store reconstituted vials at 2-8°C. Stability is typically 30 days post-reconstitution if kept cold and sterile.

Cycle and washout: 12 weeks on, 2 weeks off. The 2-week washout allows pituitary GH-pulse sensitivity to reset, preventing desensitization. After the washout, you can run another 12-week cycle or take 4 weeks off for a longer recovery window.

What to expect, week by week.

Week 1: Mild improvement in sleep quality by night 3-4. You may notice flushed skin or transient headaches as GH begins to shift fluid distribution. Appetite may increase slightly. Energy is steady, not dramatic.

Week 2: Sleep deepens further. Joint discomfort or tendon soreness from prior training may begin to resolve slightly. Some users report vivid dreams. No major body composition change yet; your CNS is re-tuning GH signalling.

Week 4: Soft-tissue recovery is noticeably faster. A minor shoulder impingement or knee soreness resolves measurably. Lean mass begins to accumulate if you are training consistently and eating at maintenance or slight surplus. Skin texture may improve subtly. Some water retention is normal.

Week 8: Defined improvements in body composition if training stimulus is present. Muscle pumps in the gym are fuller. Recovery between sessions is tangibly faster. Sleep is consistently deep. Finger tingling or carpal tunnel irritation can emerge at this point if you are predisposed; this is a sign to monitor dosing or dial back slightly.

Week 12: Cumulative lean-mass gain of 3-6 pounds is typical (depending on training and nutrition). Body-composition shifts are modest but real. Joint and tendon quality is markedly improved. At this point, enter the 2-week washout.

Side effects and safety.

CJC-1295 side-effect profile: Mild headache, transient flushing, and water retention are most common. Finger tingling or carpal tunnel exacerbation can occur at higher doses or in genetically predisposed individuals. Prolactin elevation is minimal with the non-DAC form. Cortisol does not typically rise.

Ipamorelin side-effect profile: Very low. Because Ipamorelin acts through ghrelin pathways rather than adrenergic or serotonergic systems, it carries minimal prolactin or cortisol risk. Appetite increase is the most common reported effect. Some users experience mild nausea if injected on a full stomach.

Combined risk: When stacked, the side-effect burden is additive but mild. Water retention is the most common complaint, managed by maintaining hydration and modest sodium awareness. Finger tingling or joint aches signal that dosing is at the upper end of your individual tolerance; reduce Ipamorelin to 75 micrograms per dose or extend the washout to 3 weeks.

Drug interactions: Both compounds are peptides and do not interact significantly with oral medications. If you are on thyroid replacement, ensure your TSH is stable; GH can shift thyroid function slightly. If on blood-pressure medication, monitor BP, as water retention from GH can raise readings transiently.

Clinician referral: Before starting, obtain a baseline IGF-1 level and fasting glucose. If you have any history of cancer, pituitary adenoma, or uncontrolled hypertension, consult a qualified clinician. During the cycle, consider a midpoint IGF-1 check (week 6) to confirm you are responding physiologically. These are research compounds; a clinician familiar with peptide protocols is invaluable.

Sourcing and quality.

CJC-1295 and Ipamorelin are widely available from research suppliers but variable in quality. Look for suppliers who provide third-party HPLC or mass-spec purity reports (95%+ purity is the floor). Vials should arrive sealed, with clear labelling of batch number and manufacturing date. Powder should be white to off-white, free of discoloration or clumping.

Reconstitution is straightforward but requires sterile technique. Use a laminar hood or ISO Class 5 environment if available, or at minimum a clean-air workspace with alcohol-sterilized vial tops and sterile needles. Contamination in peptide solutions is invisible but can cause infection at injection sites or systemic issues; do not cut corners here.

If you receive powder that reconstitutes to a cloudy or discoloured solution, discard it. If a supplier cannot provide purity documentation, find another source. This is non-negotiable.